文章基本信息

标题：Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital
本地全文：下载
作者：Rana Moustafa Al AdAwi ; Zainab Albu-Mahmood ; Mohamed Abdelgelil 等
期刊名称：Risk Management and Healthcare Policy
印刷版ISSN：1179-1594
电子版ISSN：1179-1594
出版年度：2021
卷号：Volume 14
页码：519-525
DOI：10.2147/RMHP.S283471
出版社：Dove Medical Press Ltd
摘要：Background :Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia. Objective :To determine the incidence of hyperkalemia and its risk factors in patients receiving co-trimoxazole. Materials and Methods :A retrospective observational study involving all patients who received co-trimoxazole between 1 January 2012 and 1 January 2013 was conducted. Subjects were identified through a list generated from a computerized pharmacy system. The patients' demographic and clinical characteristics were retrieved from electronic medical records. Data were analyzed using univariate and multivariate logistic regression. Results :One hundred sixty-one patients fulfilled the eligibility criteria. Of these, 46 (28.6%) experienced hyperkalemia. Around 35 (76%) of the patients who experienced hyperkalemia received co-administered medications that might induce hyperkalemia. The co-administration of co-trimoxazole with other medications that may induce hyperkalemia was found to be associated with higher incidence of hyperkalemia when compared to co-trimoxazole administration alone [adjusted OR 3.2, 95% CI (1.4-7.3), p=0.005]. Additionally, age > 60 years was associated with an increased risk of hyperkalemia when compared to younger age group 18-39 years [adjusted OR 6.5, 95% CI (2.1-19.7); p=0.001]. Conclusion :Co-trimoxazole use is associated with high incidence of hyperkalemia, especially among older patients and those receiving it in combination with other medications that might contribute to hyperkalemia development such as calcineurin inhibitors and β-blockers. © 2021 Al AdAwi et al.
关键词：adverse drug reaction;co-administration;co-trimoxazole;hyperkalemia;risk factors